Menu Search
Equities

NRX Pharmaceuticals Inc

NRXP:NAQ

NRX Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.26
  • Today's Change-0.01 / -0.79%
  • Shares traded113.73k
  • 1 Year change-61.81%
  • Beta1.2480
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year NRX Pharmaceuticals Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 39.75m to a smaller loss of 30.15m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-197.97%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at NRX Pharmaceuticals Inc fell by 15.46m. Cash Flow from Financing totalled 6.20m or -- of revenues. In addition the company used 21.66m for operations while cash used for investing totalled 3.00k.
Cash flow per share-0.5453
Price/Cash flow per share--
Book value per share-1.70
Tangible book value per share-1.70
More ▼

Balance sheet in USDView more

NRX Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio0.2063
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 93.41%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		71.82
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.